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Tumour cell invasion and metastasis are the hallmark of malignant neoplasm. S100A4 is a member of small calcium-binding protein
family and is involved in the cell proliferation and cancer progression. S100A4 is capable of inducing metastasis in animal models and is
associated with aggressive phenotype of human tumours. We previously identified S100A4 as a candidate gene involved in anaplastic
thyroid cancer metastasis by microarray analysis. To further determine whether S100A4 overexpression is associated with thyroid
tumour invasion and metastasis, in the present study, we examined S100A4 gene expression in six benign multinodular goitres
(MNG) and 28 matched samples of adjacent normal thyroid tissue (N), primary (T) and metastatic (M) papillary thyroid carcinomas
(PTC) by immunohistochemistry and real-time reverse transcription–polymerase chain reaction (RT-PCR) analysis. This gave us the
advantage of directly comparing levels of S100A4 expression within the same genetic background. Using immunohistochemistry, we
found that high levels of S100A4 were detected in 24 of 28 (86%) PTC specimens and their local regional lymph node or distant
metastases. No S100A4 staining was observed in normal thyroid tissues and simple MNG. However, in MNG coexistent with PTC,
moderate focal staining could be found in 11 of 15 MNG adjacent to PTC. The S100A4 was stained more intensely in invading fronts
than in central portions of both T and M. Real-time RT–PCR analysis of primary tumours and their matched lymph node metastasis
demonstrated that significantly higher S100A4 transcripts were present in metastatic tumours as compared to the primary tumours
(Po0.01). These data suggest that overexpression of S100A4 is associated with thyroid tumour invasion and metastasis and it may be
a potential target for therapeutic intervention.
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Thyroid cancers of follicular cell origin are the most common
endocrine malignancies (Kinder, 2003; Sherman, 2003). Although
the survival rate of patients with well-differentiated thyroid cancer
exceeds the rate for most other cancers, the development of
metastasis continues to be the most significant cause in thyroid
cancer mortality (Mazzaferri, 1999; Sherman, 2003). Multiple
pathogenic steps are involved in tumour invasion and metastases.
These include the proliferation and detachment of tumour cells
from the primary neoplasm, invasion of the surrounding extra-
cellular matrix, angiogenesis, vascular or lymphatic dissemination,
and eventually, homing of the tumour cells and proliferation at the
new sites (Woodhouse et al, 1997; Hanahan and Weinberg, 2000;
Liotta and Kohn, 2001). Identification of genes involved in this
process will enable us to target them for future diagnosis or
therapeutic intervention.
The S100A4 has recently emerged as an important protein with
the capacity to promote invasion and metastasis of many human
neoplasms (Barraclough, 1998; Mazzucchelli, 2002; Taylor et al,
2002; Cho et al, 2003; Lee et al, 2004; Moriyama-Kita et al, 2004).
The human S100A4 gene, located on 1q21(Schafer et al, 1995),
encodes an acidic 101 amino-acid protein with two EF-hand
motifs. These motifs consist of a consensus sequence of 12 amino
acids capable of binding Ca
2þ with high affinity and specificity
(Donato, 2001; Heizmann et al, 2002). S100A4 is member of S100
calcium-binding proteins that regulate intracellular processes such
as cell growth, motility, cell cycle, transcription and differentiation.
In all, 20 members of S100 protein family have been identified so
far, and altogether, S100 proteins represent the largest subgroup in
the EF-hand Ca
2þ-binding protein family (Heizmann et al, 2002).
S100 proteins have received increasing attention due to their close
association with several human diseases including cardiomyopathy
(Most et al, 2001, 2003; Du et al, 2002), neurodegenerative
disorders (Heizmann, 1999; Hoyaux et al, 2000), neuroprotection
(Ahlemeyer et al, 2000; Pedersen et al, 2004), and cancer (Lee et al,
2004; Lin et al, 2004). These proteins have also been shown to be
valuable markers in the diagnosis and management of these
diseases and are considered to have a potential as drug targets to
improve therapies (Kiewitz et al, 2000; Diederichs et al, 2004;
Harpio and Einarsson, 2004; Rehman et al, 2004).
We have previously demonstrated by microarray analysis that
S100A4 was highly expressed in anaplastic thyroid carcinoma cell
line with high metastatic potential (ARO/met2) as compared to its
parental cell line ARO and found that S100A4 overexpression was
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sassociated with advanced disease stage (Zou et al, 2004). Presently,
little is known about the potential role of S100A4 in thyroid
tumour invasion and metastasis. To this end, we examined S100A4
gene expression in 6 benign multinodular goitres (MNG) and 28
matched samples of adjacent normal thyroid tissue (N), primary
(T) and metastatic (M) papillary thyroid carcinomas (PTC) by
immunohistochemistry and real-time RT–PCR analysis. The
results suggest that overexpression of S100A4 may play an
important role in thyroid tumour invasion and metastasis.
MATERIALS AND METHODS
Thyroid tumour specimens
Fresh human tumour tissues with matched normal thyroid tissue
and lymph node metastasis were obtained from 10 patients at
surgery, and were immediately frozen in liquid nitrogen and stored
at  701C until processed. A pathologist confirmed that tissues
from lymph node metastases were comprised by at least 80% of
tumour tissue. A series of six benign MNG, 28 PTC with matched
local regional lymph node or distant metastases (25 with lymph
node metastasis and three with nose, lung, or brain distant
metastasis, respectively) were selected solely on the basis of tissue
availability for immunohistochemistry analysis. Among the 28
PTC samples, 24 are classic PTC, one tall cell variant and two
follicular variant of PTC. The institutional review board approved
the research project.
Immunohistochemistry analysis
A representative formalin-fixed paraffin-embedded tissue block
was chosen from the pathology archives for each of the 28 PTC and
six MNG selected for immunostaining. Normal thyroid tissues
were also contained in these tissue blocks. Sections (4mm)
mounted on poly-L-lysine-coated slide were incubated for 30min
at 601C, deparaffinised by standard methods, and placed in 0.05 M
Tris-HCI buffer, pH 7.2. Antigen retrieval was performed for
20min in 10mm sodium citrate buffer (pH 6) heated at 951Ci na
steamer, followed by cooling for 20min. After blocking endogen-
ous peroxidase activity with 0.3% aqueous hydrogen peroxide for
5min, the primary polyclonal rabbit anti-S100A4 antibody (DAKO,
Carpinteria, CA, USA) was incubated with the sections at a final
dilution of 2mgml
 1 for 30min. In immunobloting analysis using
recombinant S100A1, S100A2, S100A4, S100A6, and S100B, the
antibody recognised only S100A4. No crossreaction with the other
S100 proteins was observed. For each case, a control slide was
incubated with Tris-HCI buffer substituted for the primary
antibody. DAKO LSABþkit, HRP was used for the detection of
the immunostaining. The sections were counterstained with
Mayer’s haematoxylin. The distribution of immunolabelling was
determined from a minimum of three representative high-power
( 400) fields and categorised into three groups: 0%, negative;
1–25%, focal; and 26–100%, diffuse.
Quantitative real-time RT–PCR analysis
Total RNAs from normal thyroid, thyroid tumour, and lymph
node metastasis were extracted by quanidinium thiocyanate–
phenol–chloroform method as described previously (Shi et al,
1999). The integrity of RNA was verified by denaturing gel
electrophoresis. Of total RNA, 2mg were reverse-transcribed using
Promega reverse transcription system (Promega, Madison, WI,
USA). LightCycler DNA Master SYBR Green 1kit was used for
quantitative real-time PCR analysis according to the manufac-
turer’s protocols (Roche, Mannheim, Germany). The cDNA
mix was diluted 10-fold and 2ml of the dilution were used for
real-time PCR analysis. PCR primers for 440bp S100A4 cDNA
fragment were 50-TCTTTCTTGGTTTGATCCTG-30 (sense) and
50-GCATCAAGCACGTGTCTGAA-30 (antisense). The sense primer
spans over the intron 1(938bp) so that the contaminating genomic
DNA would not be amplified as the expected 440bp cDNA
fragment. The mRNA level of housekeeping gene glyceraldehydes-
3-phosphate dehydrogenase (GAPDH) was used as an internal
control and a 300bp PCR product was amplified using the
following two primers: 50-ACAGTCAGCCGCATCTTCTT-30 (sense)
and 50-TTGATTTTGGAGGGATCTCG-30 (antisense). The PCR
conditions are 951C for 30s followed by 40 cycles of amplification
(951C for 10s, 481C for 5s, and 721C for 10s). The resulting
concentration of S100A4 PCR products were normalised by
comparison with GAPDH and was used to determine the mRNA
level of S100A4 among thyroid tumour specimens.
Statistical analysis
The significant difference of S100A4 gene expression between
specimen groups was carried out using the unpaired Student’s t-
test. Differences were considered statistically significant when the
P-value was o0.05.
RESULTS
Immunohistochemical analysis of S100A4 expression in
papillary thyroid cancer specimens
We demonstrated previously the S100A4 overexpression in
advanced stage of thyroid carcinomas by Northern blot and real-
time RT–PCR analysis. To examine the expression of S100A4 at
the cellular level, we performed immunohistochemical analyses
using histochemical preparations of formalin-fixed paraffin-
embedded surgical specimens. Normal thyroid follicular cells were
not stained with the S100A4 antibody (Figure 1A). No immuno-
staining was found in samples incubated with the secondary
antibodies in the absence of primary antibodies (Figure 1C).
Strong immunostaining was present in some lymphocytes,
dendritic cells, and fibroblast-like reactive stroma cells in the
thyroid tissues and lymph nodes usually surrounding the germinal
centres (Figure 1E and F), which served as an internal positive
control as previously reported (Rudland et al, 2000; Rosty et al,
2002). As shown in Table 1, S100A4 immunostaining was detected
in 24 out of 28 (86%) PTC specimens: 21 with diffuse staining
(staining was present in more than 25% of tumour cells) and three
with focal staining (staining was present in o25% of tumour cells).
In these S100A4-positive PTC samples, stronger staining was often
observed at the tumour-invading front (Figure 2B and E) as
compared to the central region (Figure 2A and D). In general,
metastatic PTC samples had stronger staining (Figure 2C and F)
when compared with their matched primary tumours (Figure 2A
and D). There are two cases where positive staining was found in
the metastatic lymph nodes and negative staining in the primary
tumours. Therefore, 26 metastatic PTCs were S100A4 positive. We
next compared the intensity of S100A4 staining between primary
and metastatic PTCs. In all, 17 out of 24 (71%) metastatic PTCs
were found to have stronger immunostaining than their matched
primary PTC samples: 14 with local regional lymph node
metastasis and three with distant metastases (one metastasised to
the nose 8 years after treatment, and the other two metastasised to
the lung and brain frontal lobe, respectively at the time of
diagnosis) (Figure 3). Equal intensity of staining was found in the
remaining seven metastatic tumours as compared to the primary
tumours. S100A4 staining was mainly cytoplasmic, heterogeneous
in some tumours with tendency to more intense staining in
invading fronts than in central portions of the tumour samples.
Striking nuclear staining was found in five tumour samples: three
with distant metastasis to nose, lung or brain frontal lobe (TNM
stage IV), and the other two with stage III tumours, indicating that
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snuclear staining may be associated with aggressive behaviour of
the cancer (Figure 3). Among the four primary PTC samples with
negative S100A4 staining, strong staining was observed in two
matched lymph node metastasis tumour tissues. Interestingly, in
11 out of 15 cases where MNG were next to PTC, focal moderate
cytoplasmic and nuclear staining could be found in MNG (Figure 4,
upper panels A and B) as compared to the stronger staining in PTC
(Figure 4, upper panels C and D). Examination of the same MNG
area stained by haematoxylin and eosin failed to show the
diagnostic nuclear features of PTC such as clearing of the
nucleoplasm, peripheral margination of chromatin, or nuclear
grooves, although subtle nuclear atypia manifesting as nucleo-
megaly and slight irregularity of the nuclear membrane was
evident (Figure 4, lower panels A and B). These features were,
however, present in the PTC area of the same patient (Figure 4,
lower panels C and D). However, in the six cases with simple MNG,
none of them labelled by S100A4 (Figure 1B).
Analysis of thyroid tumour specimens for S100A4 gene
expression by quantitative real-time RT–PCR analysis
Since S100A4 was intensely immunostained in metastatic tumours
as compared to the primary tumours, we wondered whether its
mRNA transcripts were also increased to the same degree as its
protein expression. To this end, we analysed S100A4 transcripts
from 10 patients with matched tissues of normal thyroid, PTC and
lymph node metastasis by real-time RT–PCR. As shown in
Figure 5, significantly higher S100A4 expression was seen in
metastatic tumours as compared to primary tumours (Po0.01)
even though S100A4 overexpression was present in primary
tumours when compared with normal thyroid tissue (Po0.01).
These data suggest that S100A4 overexpression was involved in
tumour invasion and metastasis.
DISCUSSION
S100A4 is known to be involved in the tumour invasion and
metastasis by virtue of its ability to activate nonmuscle myosin
(Ford et al, 1997; Takenaga et al, 1997a; Bjornland et al, 1999; Li
et al, 2003; Jenkinson et al, 2004). However, information on
S100A4 expression in thyroid tumour cells is limited thus far,
although high S100A4 expression in breast, ovary, colon, gastric,
and pancreatic carcinomas has been reported (Mazzucchelli, 2002).
In an early study, we have shown increased S100A4 expression in
thyroid carcinoma specimens with advanced disease stage and
indicated that it may be a useful prognostic marker for thyroid
carcinoma (Zou et al, 2004). In the present study, we have shown
increased S100A4 expression in thyroid tumour cells metastasised
to regional lymph nodes or distant organs and at the tumour
invasion front in matched primary thyroid tumour and their
metastatic specimens. These findings provide further support that
S100A4 is involved in thyroid cancer invasion and metastasis.
Since S100A4 is expressed in a variety of cell types such as
lymphocytes, dendritic cells, macrophages, and smooth muscles
(Takenaga et al, 1997b; Rudland et al, 2000), it is important to
examine S100A4 expression at the cellular level to ascertain that
higher expression of S100A4 mRNA in thyroid carcinoma speci-
mens reflects the expression in thyroid carcinoma cells themselves.
Figure 1 S100A4 immunostaining of tissues from normal thyroid, benign multinodular goitre, primary papillary thyroid carcinoma, and its lymph node
metastasis. Negative staining in both normal thyroid (A,  100) and multinodular goitre (B,  100); negative staining of papillary thyroid carcinoma with a
secondary anti-rabbit antibody only (C,  100) and positive staining of the same tissue when S100A4 antibody was added (D,  100); focal lymph node
metastasis of papillary thyroid carcinoma stained with S100A4 (E,  100). An arrow indicated the metastatic foci. Strong staining of some lymphocytes,
dendritic, and stromal cells were also shown surrounding the germinal centre, which is not stained (E,  100; F,  200).
Table 1 S100A4 immunostaining in MNG and PTC from primary and
metastatic regions
Simple
MNG
MNG adjacent
to PTC
Primary
PTC
Metastatic
PTC
S100A4 labelling (n¼6) (n¼15) (n¼28) (n¼28)
Negative 6 4 4 2
Focal (1–25%) 11 3 2
Diffuse (26–100%) 21 24
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sTo evaluate this point and examine more closely the S100A4
expression in invasive and metastatic cells, we performed
immunohistochemical analysis using polyclonal rabbit anti-
S100A4 antibody. Strong immunostaining was observed at the
tumour invading front and metastatic site. This observation is
further confirmed by quantitative real-time RT–PCR analysis,
which shows higher S100A4 mRNA in lymph node metastasis as
compared to primary tumours, supporting the role of S100A4 in
cell motility and invasion (Ninomiya et al, 2001). Previous
immunohistochemical studies of S100A4 showed an overexpres-
Figure 2 Immunostaining of primary and metastatic papillary thyroid carcinoma cells with anti-S100A4 polyclonal antibody from the same patient. Weak
cytoplasmic labelling of papillary thyroid carcinoma cells in the central portion of the tumour at the magnifications  100 (A) and  200 (D). Strong
cytoplasmic labelling of carcinoma cells at the invading front of primary tumour  100 (B) and  200 (E), and in metastatic lymph node at the
magnifications of  100 (C) and  200 (F).
Figure 3 Nuclear staining of papillary thyroid carcinoma cells with anti-S100A4 polyclonal antibody. Weak cytoplasmic and strong nuclear labelling of
primary PTC (A,  100; D,  200) in a patient who developed distant metastasis (carcinoma cells metastasised to nose) 8 years after surgical removal of
the primary thyroid tumour. Stronger cytoplasmic and nuclear labelling of the metastatic PTC is shown from the same patient (B,  100; E,  200). Weak
cytoplasmic and strong nuclear labelling of primary PTC is shown in another patient (C,  200). Stronger cytoplasmic and nuclear labelling of papillary
thyroid carcinoma cells that metastasised to a regional lymph node of the same patient who later developed lung metastasis 1 year after treatment (F,
 200).
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ssion in 41% of breast carcinomas (Rudland et al, 2000), 55% of
gastric carcinomas (Yonemura et al, 2000), 94% of colorectal
adenocarcinomas (Takenaga et al, 1997b), 93% of invasive
pancreatic carcinomas (Rosty et al, 2002), and 25% of oesophageal
squamous carcinoma. Using tissue microarrays, Cross et al (2005)
has recently demonstrated that S100A6, S100A8, S100A9, and
S100A11 are all expressed in common cancers, especially breast
cancer. Moreover, they found a translocation of S100A11 expres-
sion from exclusively nuclear location in normal tissues to
cytoplasmic and nuclear in all common cancers. We instead found
a translocation of S100A4 expression from cytoplasmic to nuclear
in five samples with advanced disease stage, suggesting that
Figure 4 Focal S100A4 immunostaining of thyroid follicular cells in a multinodular goitre coexisted with papillary thyroid carcinoma. Moderate focal
cytoplasmic and nuclear labelling of thyroid follicular cells can be seen in a multinodular goitre (upper panel: A,  100; B,  200), which is adjacent to
papillary thyroid carcinoma. Strong labelling was shown in thyroid papillary carcinoma cells at the invading front from the same patient (upper panel: C,
 100; D,  200). The lower panel shows the conventional haematoxylin and eosin staining of the corresponding areas shown in the upper panel.
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proliferation or metastatic potential of the cancer cells. Flatmark
et al (2003) has demonstrated that S100A4 nuclear localisation
correlated with tumour stage and aggressiveness of colorectal
carcinoma. A recent study has shown that A100A1, another
member of the S100 family of proteins, can interact with S100A4 to
modulate the effect of S100A4 on their metastatic abilities (Wang
et al, 2005).
Although it remained unclear what causes S100A4 overexpres-
sion in thyroid carcinomas, it has been shown that hypomethyla-
tion of S100A4 gene correlates with gene activation and
overexpression in human pancreatic carcinomas and colon
adenocarcinoma cell lines (Nakamura and Takenaga, 1998; Rosty
et al, 2002). Hypomethylation of the first (Rosty et al, 2002) and
second introns (Nakamura and Takenaga, 1998) were well
correlated with the expression of S100A4. The addition of 5-Aza-
20-deoxycytidine, an inhibitor of the eukaryotic DNA methyl-
transferase, induced the expression of the S100A4 gene in colon
adenocarcinoma cell lines (Nakamura and Takenaga, 1998). In
humans, the gene for S100A4 occurs in a cluster of 13 S100 genes
on chromosome 1q21 (Schafer et al, 1995; Heizmann et al, 2002).
Gain of 1q and loss of 9q21.3–q32 have been reported to be
associated with a less favourable prognosis in papillary thyroid
carcinoma using comparative genomic hybridisation (Kjellman
et al, 2001). Gain of 1q and loss of 9q21.3–q32 are exclusively seen
in tumours from patients with aggressive disease, and the presence
of distant metastases is associated with gain of 1q. It is possible
that S100A4 may be one of those genes involved in the gain of 1q
given that S100A4 is located in 1q21 region.
In the rodent model systems, elevated levels of S100A4 can only
synergise with growth-promoting oncogenic products such as c-
erbB-2/neu (Davies et al, 1996) or have to be expressed in benign
tumours before metastasis can be induced (Lloyd et al, 1998).
Transgenic mouse studies have demonstrated that S100A4 by itself
is not able to initiate tumours or induce metastatic effect in normal
rodent cells (Davies et al, 1995). However, it did induce metastatic
disease of cells that had been initiated by oncogenes such as c-
erbB-2/neu. When S100A4 transgenic mice were mated with neu
transgenic mice, known for developing mammary cancer after
multiple pregnancies, double-positive offspring that inherited both
genes developed mammary tumours with significantly more lung
metastases than mice that inherited only the neu oncogene (Davies
et al, 1996). Overexpression of c-erbB-2/neu has been previously
reported in PTC, and PTC without distant metastases showed
significantly less cytoplasmic immunostaining than those with
development of metastases (Haugen et al, 1992; Kremser et al,
2003). Taken together with our findings of S100A4 overexpression
in advanced thyroid tumours, the transgenic mouse model may fit
well with human PTC, implicating that S100A4 may enhance
thyroid cancer invasion and metastasis in cooperation with c-
erbB-2/neu. Interestingly, mice with a germline inactivation of the
S100A4 gene have been found to develop spontaneous tumours as
a result of destabilisation of the apoptosis-promoting function of
p53 tumour suppressor gene. However, tumours developed in
these mice were nonmetastatic (EL Naaman et al, 2004).
In contrast to the negative immunostaining in specimens of
simple multinodular goitre, we detected focal immunostaining of
MNG that was adjacent to papillary thyroid carcinoma. Although it
is not clear what leads to the focal overexpression of S100A4, it
may be resulted from local demethylation or hypomethylation, one
of the early events in tumour development. Overexpression of
S100A4 induced by this epigenetic event may contribute to
abrogation of apoptosis and tumorigenesis (EL Naaman et al,
2004). It may also be an early sign of malignant transformation
resulting from genetic mutations leading to oncogene activation
and/or inactivation of tumour suppressor genes. This hypothesis
was supported by transgenic mouse studies described above and
previous studies demonstrating mutations of several oncogenes
(ras, TRK, and gsp), tumour supperssor genes such as FHIT, and
mitochondrial genes in benign MNG (Shi et al, 1991; Farid et al,
1995; Zou et al, 1999; Abu-Amero et al, 2005). Although these
S100A4-positive cells lack characteristic morphological feature of
PTC, we suggest that positive staining for S100A4 of a MNG should
alert pathologist to the coexistence of PTC foci and should be
verified in a large series of specimens.
In summary, we have investigated S100A4 expression at the
molecular and cellular level in matched primary and metastatic
PTC specimens. High levels of S100A4 were detected in 24 of 28
(86%) PTC specimens and their local regional lymph node or
distant metastasis. The S100A4 expression was much higher
at the tumour-invading front and in the metastatic tumours as
compared to the primary tumours. These data suggest that
overexpression of S100A4 is associated with thyroid tumour
invasion and metastasis and it may be a potential target for
therapeutic intervention.
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